Why the study?
Does ethmozin reduce ventricular premature complexes in patients with chronic, persistent, frequent and symptomatic VPCs?
Population
37 patients with chronic, persistent, frequent and symptomatic ventricular premature complexes (VPCs)
Comparison
Ethmozin 225 mg/day or 600 mg/day vs Placebo
Design
Cohort, single-blind (for placebo phase)
Follow-up
minimum of 4 days
Authors
Loading...
May support higher-dose ethmozin for symptomatic VPCs; leaves open efficacy and safety without randomized trials.
Does ethmozin reduce ventricular premature complexes in patients with chronic, persistent, frequent and symptomatic VPCs?
Ethmozin at 600 mg/day appears to be a well-tolerated and effective agent for suppressing ventricular premature complexes.
Podrid et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: